02.19.25 -- Day One Bio Aims To Shorten The Time Gap On Cancer Treatments For Kids

From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, joins the Business of Biotech to discuss his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. From mastering in-house manufacturing to forging strategic partnerships, Capsida aims to redefine genetic medicine. Listen now!

To preserve the quality of care and build a more effective approach to trial design, a sponsor must consider their approach to patient recruitment and enrollment early and often.

The best way to address clinical trial recruitment challenges is with a multifaceted approach that goes beyond traditional channels and ways of thinking.

By embracing innovative trial models and strategic collaborations, oncology CROs play a pivotal role in bringing novel cancer therapies to market efficiently and effectively.

Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.

Recent advancements in genetic engineering, analytics, and screening reimagine E. coli as an “optimal” protein factory, not just a common one or an expression system artifact.

A clear path for establishing equivalency is needed to facilitate more rapid advances in the gene therapy field and ultimately to enable lower-cost gene therapies that reach patients faster than ever.